137 related articles for article (PubMed ID: 33823101)
1. Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents.
Apperley LJ; Gait L; Erlandson-Parry K; Laing P; Senniappan S
J Pediatr Endocrinol Metab; 2021 May; 34(5):613-618. PubMed ID: 33823101
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Kelly AS; Auerbach P; Barrientos-Perez M; Gies I; Hale PM; Marcus C; Mastrandrea LD; Prabhu N; Arslanian S;
N Engl J Med; 2020 May; 382(22):2117-2128. PubMed ID: 32233338
[TBL] [Abstract][Full Text] [Related]
3. Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study.
Capristo E; Panunzi S; De Gaetano A; Raffaelli M; Guidone C; Iaconelli A; L'Abbate L; Birkenfeld AL; Bellantone R; Bornstein SR; Mingrone G
Diabetes Metab; 2018 Jun; 44(3):235-242. PubMed ID: 29398254
[TBL] [Abstract][Full Text] [Related]
4. Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial.
Bensignor MO; Bramante CT; Bomberg EM; Fox CK; Hale PM; Kelly AS; Mamadi R; Prabhu N; Harder-Lauridsen NM; Gross AC
Pediatr Obes; 2023 Sep; 18(9):e13061. PubMed ID: 37264767
[TBL] [Abstract][Full Text] [Related]
5. Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg.
Tronieri JS; Wadden TA; Walsh O; Berkowitz RI; Alamuddin N; Chao AM
Behav Res Ther; 2020 Aug; 131():103639. PubMed ID: 32450367
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.
Danne T; Biester T; Kapitzke K; Jacobsen SH; Jacobsen LV; Petri KCC; Hale PM; Kordonouri O
J Pediatr; 2017 Feb; 181():146-153.e3. PubMed ID: 27979579
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.
Mastrandrea LD; Witten L; Carlsson Petri KC; Hale PM; Hedman HK; Riesenberg RA
Pediatr Obes; 2019 May; 14(5):e12495. PubMed ID: 30653847
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide Does Not Adversely Impact Fat-Free Mass Loss.
Grannell A; Martin WP; Dehestani B; Al-Najim W; Murphy JC; le Roux CW
Obesity (Silver Spring); 2021 Mar; 29(3):529-534. PubMed ID: 33528919
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
[TBL] [Abstract][Full Text] [Related]
10. [Impact on weight loss and body composition of a food education intervention associated with Liraglutide treatment to address obesity].
Dearos Sanchis M; Voltas Arribas B; Carrasco-Querol N; Sauras Colón E; Sánchez Juan C
Nutr Hosp; 2024 Jun; 41(3):585-593. PubMed ID: 38450509
[TBL] [Abstract][Full Text] [Related]
11. The effect of weight management interventions that include a diet component on weight-related outcomes in pregnant and postpartum women: a systematic review protocol.
Spencer L; Rollo M; Hauck Y; MacDonald-Wicks L; Wood L; Hutchesson M; Giglia R; Smith R; Collins C
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):88-98. PubMed ID: 26447010
[TBL] [Abstract][Full Text] [Related]
12. Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial.
Wadden TA; Walsh OA; Berkowitz RI; Chao AM; Alamuddin N; Gruber K; Leonard S; Mugler K; Bakizada Z; Tronieri JS
Obesity (Silver Spring); 2019 Jan; 27(1):75-86. PubMed ID: 30421856
[TBL] [Abstract][Full Text] [Related]
13. Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
Tronieri JS; Fabricatore AN; Wadden TA; Auerbach P; Endahl L; Sugimoto D; Rubino D
Obes Facts; 2020; 13(6):572-583. PubMed ID: 33197917
[TBL] [Abstract][Full Text] [Related]
14. Baseline Dietary Restraint Predicts Negative Treatment Outcomes after 12 Months in Children and Adolescents with Obesity Participating in a Lifestyle Intervention.
Albayrak Ö; Pott W; Hebebrand J; de Zwaan M; Pauli-Pott U
Obes Facts; 2019; 12(2):179-189. PubMed ID: 30893684
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.
Park JH; Kim JY; Choi JH; Park HS; Shin HY; Lee JM; Kim JW; Ko HJ; Chon S; Kim BK; Kim CS; Lim S
Int J Obes (Lond); 2021 Apr; 45(4):776-786. PubMed ID: 33473176
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.
Khoo J; Hsiang JC; Taneja R; Koo SH; Soon GH; Kam CJ; Law NM; Ang TL
Liver Int; 2019 May; 39(5):941-949. PubMed ID: 30721572
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
18. Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology.
Chao AM; Wadden TA; Walsh OA; Gruber KA; Alamuddin N; Berkowitz RI; Tronieri JS
Obesity (Silver Spring); 2019 Dec; 27(12):2005-2010. PubMed ID: 31746553
[TBL] [Abstract][Full Text] [Related]
19. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
20. Use of a Mobile Lifestyle Intervention App as an Early Intervention for Adolescents With Obesity: Single-Cohort Study.
Chew CSE; Davis C; Lim JKE; Lim CMM; Tan YZH; Oh JY; Rajasegaran K; Chia YHM; Finkelstein EA
J Med Internet Res; 2021 Sep; 23(9):e20520. PubMed ID: 34581672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
